Context

Helicobacter pylori infection is the main cause of several gastric diseases including gastritis, peptic ulcer and gastric cancer. Traditional anti-H. pylori treatments fail in up to 20–30% of naive patients requiring intervention. Failed attempts may cause the acquisition of resistance by H. pylori or the selection of resistant/resilient strains, hindering second-line treatments.

One of the most recommended second-line regimens is triple therapy with levofloxacin (LT); however, its efficacy has never been optimal, with an estimated pooled eradication rate of 79%.1 In order to improve these results, Liou and colleagues performed a randomised trial comparing LT with a levofloxacin containing sequential therapy (LS).